| P2093 | author name string | Li Liu | |
| | Dawei Xu | |
| | Magnus Björkholm | |
| | Kun Wang | |
| | Liu Yang | |
| | Nan Ge | |
| | Tiantian Liu | |
| | Cheng Liu | |
| | Shengtian Zhao | |
| | Feng Kong | |
| | Xiaotian Yuan | |
| | Yidong Fan | |
| P2860 | cites work | Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. | Q38874534 |
| | The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas | Q39076273 |
| | Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome | Q39098321 |
| | Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications | Q39904379 |
| | Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients | Q40752079 |
| | Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma | Q43128951 |
| | Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation | Q45823928 |
| | Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. | Q52034595 |
| | FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. | Q52857898 |
| | Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. | Q52956152 |
| | TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. | Q54347306 |
| | FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies | Q57259742 |
| | Human telomerase and its regulation | Q24533247 |
| | FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. | Q33347229 |
| | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas | Q33688439 |
| | Regulation of the human catalytic subunit of telomerase (hTERT). | Q34180715 |
| | TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR | Q35068013 |
| | TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer | Q35151119 |
| | Genomic Characterization of Upper Tract Urothelial Carcinoma | Q36362571 |
| | TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 |
| | Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target | Q36958930 |
| | TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism | Q37256055 |
| | Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder | Q37730596 |
| | Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer | Q37786089 |
| | Biomarkers for bladder cancer aggressiveness | Q38028813 |
| | European guidelines on upper tract urothelial carcinomas: 2013 update | Q38094307 |
| | TERT promoter mutations in cancer development | Q38198430 |
| | Telomerase as a "stemness" enzyme | Q38211826 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 25826-25835 | |
| P577 | publication date | 2016-03-26 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients | |
| P478 | volume | 7 | |